Palmitoylethanolamide (544-31-0) is an endogenous cannabinoid. Weak ligand for CB1 (Ki= 23.8 μM) and CB2 (Ki = 13.9 μM) receptors. Inhibits fatty acid amide hydrolase (FAAH) ((IC50 = 5.1 μM). Modulates mast cell activation. Palmitoylethanolamide displays immunosuppressant, anti-inflammatory and anti-nociceptive activity.
1) De Filippis et al. (2011), Palmitoylethanolamide reduces granuloma-induced hyperalgesia by modulation of mast cell activation in rats; Mol. Pain, 7 3
2) Re et al. (2007), Palmitoylethanolamide, endocannabinoids and related cannabimimetic compounds in protection against tissue inflammation and pain: potential use in campanion animals; Vet J., 173 21
3) Lambert et al. (2002), The palmitoylethanolamide family: a new class of anti-inflammatory agents?; Curr. Med. Chem., 9 663